Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021066922 - ANTIVIRAL HETEROCYCLIC COMPOUNDS

Publication Number WO/2021/066922
Publication Date 08.04.2021
International Application No. PCT/US2020/042264
International Filing Date 16.07.2020
IPC
A61K 31/5415 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
5415ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61P 31/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C07D 417/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Applicants
  • ENANTA PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • SZYMANIAK, Adam
  • McGRATH, Kevin
  • YU, Jianming
  • MANN, Tyler
  • NGUYEN, Long
  • ZHU, Kaicheng
  • KIM, In, Jong
  • OR, Yat, Sun
Agents
  • HARLAN, Edgar, W.
Priority Data
62/910,71204.10.2019US
62/959,23010.01.2020US
63/038,23412.06.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIVIRAL HETEROCYCLIC COMPOUNDS
(FR) COMPOSÉS HÉTÉROCYCLIQUES ANTIVIRAUX
Abstract
(EN)
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
(FR)
La présente invention concerne des composés de formule (I), ou des sels, esters ou promédicaments pharmaceutiquement acceptables de ceux-ci : qui inhibent les inhibiteurs du virus respiratoire syncytial humain (VRSH) ou du métapneumovirus humain (MPVH). La présente invention concerne en outre des compositions pharmaceutiques comprenant les composés susmentionnés pour une administration à un sujet atteint d'une infection à VRSH ou MPVH. L'invention concerne également des procédés de traitement d'une infection à VRSH ou MPVH chez un sujet par administration d'une composition pharmaceutique comprenant les composés de la présente invention.
Latest bibliographic data on file with the International Bureau